V. A. Pushkarev
V. A. Pushkarev has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- A. V. Pushkarev
Republican Clinical Oncology Dispensary
3 shared publications - Александр Валерьевич Султанбаев
Bashkir State Medical University; Republican Clinical Oncology Dispensary
3 shared publications - Konstantin V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
2 shared publications M. G. Galeev
Bashkir State Medical University
2 shared publicationsA. V. Pushkarev
Republican Clinical Oncological Dispensary
1 shared publication- Adel A. Izmailov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
1 shared publication
Latest Publications
- Open Access
- 5 November 2022
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 21 (5) , 128-137
Benign breast tumors and risk factors for their development
Introduction. Benign mammary gland tumors constitute a group of heterogeneous diseases with a complex clinical and morphological structure that complicates timely diagnosis and terminological designation of pathological processes. They are of great interest because of their possible background for oncologic pathology. The most widespread disease is mastopathy, its occurrence rate in the population reaches 40%. The incidence of mastopathies increases by the age of 45 years, and then tends to decrease in the pre- and postmenopausal periods. The purpose of the review was to evaluate and analyze the literature data on the presented problem in recent years. Materials and methods. Publications of domestic and foreign authors on benign breast neoplasms and risk factors of this pathology over the past 20 years have been included in the article. Literature search was performed in the systems Scopus, Web of Science, PubMed, Elibrary. Results and discussion. Etiopathogenetic factors in patients with benign mammary gland tumors play a paramount role, substantiating the necessity of prognostication and prevention of the disease. Risk factors for these diseases include hereditary, hormonal, neuropsychological, reproductive data, age, lactation, inflammation, trauma, smoking, and others. Conclusion. The current dynamic of increasing the incidence of benign mammary tumors has been noted, but no specific risk factors for this group of diseases have been identified, as they are multifactorial, associated with genetic causes, somatic health data, and environmental influences. Not all women are equally at risk of developing breast diseases, the reasons characterizing the individual propensity for this pathology have been identified. The risk factors do not cause the development of the disease, but considerably increase its probability. The study of predisposing risk factors for the development of tumor processes in the mammary glands in order to diagnose them early gives an opportunity to improve the results and prognosis of treatment.
- 5 November 2022
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 21 (5) , 128-137
Open AccessBenign breast tumors and risk factors for their development
Introduction. Benign mammary gland tumors constitute a group of heterogeneous diseases with a complex clinical and morphological structure that complicates timely diagnosis and terminological designation of pathological processes. They are of great interest because of their possible background for oncologic pathology. The most widespread disease is mastopathy, its occurrence rate in the population reaches 40%. The incidence of mastopathies increases by the age of 45 years, and then tends to decrease in the pre- and postmenopausal periods. The purpose of the review was to evaluate and analyze the literature data on the presented problem in recent years. Materials and methods. Publications of domestic and foreign authors on benign breast neoplasms and risk factors of this pathology over the past 20 years have been included in the article. Literature search was performed in the systems Scopus, Web of Science, PubMed, Elibrary. Results and discussion. Etiopathogenetic factors in patients with benign mammary gland tumors play a paramount role, substantiating the necessity of prognostication and prevention of the disease. Risk factors for these diseases include hereditary, hormonal, neuropsychological, reproductive data, age, lactation, inflammation, trauma, smoking, and others. Conclusion. The current dynamic of increasing the incidence of benign mammary tumors has been noted, but no specific risk factors for this group of diseases have been identified, as they are multifactorial, associated with genetic causes, somatic health data, and environmental influences. Not all women are equally at risk of developing breast diseases, the reasons characterizing the individual propensity for this pathology have been identified. The risk factors do not cause the development of the disease, but considerably increase its probability. The study of predisposing risk factors for the development of tumor processes in the mammary glands in order to diagnose them early gives an opportunity to improve the results and prognosis of treatment.
- Open Access
- 16 June 2021
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 17 (1) , 35-44
Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
Descripton of metastatic HER2-positive breast cancer clinical case is introduced, multilineal strategy basing on clinical situation and disease features is justified, justification of the choice of anti-HER2 treatment in every line is made, in compliance with russian and foreigh oncology associations guidelines, along with comparance of rutine treatment results and randomised trials data.
- 16 June 2021
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 17 (1) , 35-44
Open AccessMultilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
Descripton of metastatic HER2-positive breast cancer clinical case is introduced, multilineal strategy basing on clinical situation and disease features is justified, justification of the choice of anti-HER2 treatment in every line is made, in compliance with russian and foreigh oncology associations guidelines, along with comparance of rutine treatment results and randomised trials data.
- Open Access
- 22 May 2021
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 11 (2) , 157-165
Genetic Predictors of Malignancy: a Literature Review
The review covers recent research on cancer as a genetic disease manifesting both sporadically and in germline through variant genomic mutations or DNA rearrangements. This change can be point mutations, chromosomal aberrations or hypermethylation leading to DNA repair failures. Defects in tumour suppressor genes (BRCA1, BRCA2, CHEK2, PTCH1, etc.) underly hereditary predisposition to breast cancer (BC) and ovarian cancer (OC) due to genome instability. Studying somatic mutations is key to the understanding of carcinogenesis mechanisms and finding apt therapies. Heterogeneity of cancers renders the tumour mutation profiling uneasy. The treatment choice and efficacy in BC and OC depends on homologous recombination defects in tumour cells usually imposed by damaged BRCA1/2 genes. CHEK2- associated neoplasms account for most hereditary BCs linked to flaws in the DNA repair machinery. Overexpression of the PTCH1 protein is the target in breast, lung, ovarian, colonic cancers, etc.Genetic research has fundamentally altered our understanding of the aetiology and pathogenesis of human malignancy. The molecular cancer phenotype is of paramount importance in the disease prognosis and treatment personalisation.
- 22 May 2021
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 11 (2) , 157-165
Open AccessGenetic Predictors of Malignancy: a Literature Review
The review covers recent research on cancer as a genetic disease manifesting both sporadically and in germline through variant genomic mutations or DNA rearrangements. This change can be point mutations, chromosomal aberrations or hypermethylation leading to DNA repair failures. Defects in tumour suppressor genes (BRCA1, BRCA2, CHEK2, PTCH1, etc.) underly hereditary predisposition to breast cancer (BC) and ovarian cancer (OC) due to genome instability. Studying somatic mutations is key to the understanding of carcinogenesis mechanisms and finding apt therapies. Heterogeneity of cancers renders the tumour mutation profiling uneasy. The treatment choice and efficacy in BC and OC depends on homologous recombination defects in tumour cells usually imposed by damaged BRCA1/2 genes. CHEK2- associated neoplasms account for most hereditary BCs linked to flaws in the DNA repair machinery. Overexpression of the PTCH1 protein is the target in breast, lung, ovarian, colonic cancers, etc.Genetic research has fundamentally altered our understanding of the aetiology and pathogenesis of human malignancy. The molecular cancer phenotype is of paramount importance in the disease prognosis and treatment personalisation.
- Open Access
- 26 July 2020
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 10 (2) , 143-148
Radiogenic Vaginal Angiosarcoma: a Clinical Case
Background. Vaginal sarcomas are rare malignant mesenchymal neoplasms. Incidence rate of vulvar and vaginal sarcomas ranges from 1 to 3%. Vaginal sarcomas are usually represented by leiomyosarcomas in reproductive-age women. More seldom are soft tissue fibrosarcomas, angiosarcomas, malignant fi brous histiocytomas and alveolar soft tissue sarcomas. Tumours induced by prior radiation therapy deserve special concern. In oncogynaecology, radiation therapy is commonly applied in cervical and endometrial cancer therapy. According to some evidence, average development time of a secondary tumour after completion of radiation therapy is 10.8 years. The relative risk of vaginal cancer increases by a factor of 300 after radiation therapy.Materials and methods. The reported clinical case represents a rare vaginal tumour, angiosarcoma, developed 26 years after radiation therapy for gynaecological cancer.Results and discussion. A 78 years-old patient underwent combined tumourectomy of the posterior vaginal wall with resection of the anterior rectal wall and application of preventive transversostoma. No postoperative complications were observed.Conclusion. Surgical treatment is a method of choice with patients of such kind and allows local containment of the disease.
- 26 July 2020
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 10 (2) , 143-148
Open AccessRadiogenic Vaginal Angiosarcoma: a Clinical Case
Background. Vaginal sarcomas are rare malignant mesenchymal neoplasms. Incidence rate of vulvar and vaginal sarcomas ranges from 1 to 3%. Vaginal sarcomas are usually represented by leiomyosarcomas in reproductive-age women. More seldom are soft tissue fibrosarcomas, angiosarcomas, malignant fi brous histiocytomas and alveolar soft tissue sarcomas. Tumours induced by prior radiation therapy deserve special concern. In oncogynaecology, radiation therapy is commonly applied in cervical and endometrial cancer therapy. According to some evidence, average development time of a secondary tumour after completion of radiation therapy is 10.8 years. The relative risk of vaginal cancer increases by a factor of 300 after radiation therapy.Materials and methods. The reported clinical case represents a rare vaginal tumour, angiosarcoma, developed 26 years after radiation therapy for gynaecological cancer.Results and discussion. A 78 years-old patient underwent combined tumourectomy of the posterior vaginal wall with resection of the anterior rectal wall and application of preventive transversostoma. No postoperative complications were observed.Conclusion. Surgical treatment is a method of choice with patients of such kind and allows local containment of the disease.